Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Corrective and Preventative Actions (CAPA)

Posted on By

Protocol for Implementing CAPA in BA/BE Study Facilities

Purpose

The purpose of this Standard Operating Procedure (SOP) is to define the process for identifying, implementing, and verifying corrective and preventative actions (CAPA) to address non-conformities, deficiencies, and potential risks identified during Bioavailability (BA) and Bioequivalence (BE) studies in the pharmaceutical industry.

Scope

This SOP applies to all personnel involved in the CAPA process, including Study Coordinators, Quality Assurance (QA) Officers, Laboratory Managers, and Regulatory Affairs Specialists.

Responsibilities

  • The Study Coordinator is responsible for initiating CAPA requests, coordinating CAPA activities, and ensuring timely implementation of CAPA plans.
  • The Quality Assurance (QA) Officer is responsible for overseeing the CAPA process, reviewing CAPA requests, and verifying the effectiveness of CAPA actions.
  • The Laboratory Manager is responsible for identifying non-conformities and potential risks in laboratory operations, recommending CAPA actions, and monitoring their implementation.
  • The Regulatory Affairs Specialist is responsible for ensuring that CAPA activities comply with regulatory requirements and communicating CAPA outcomes to regulatory authorities, as necessary.
See also  SOP for Handling Unblinding Procedures

Procedure

  1. Identify non-conformities, deficiencies, deviations, and potential risks through internal audits, inspections, monitoring activities, or incident investigations.
  2. Document non-conformities and their impact on study conduct, data integrity, participant safety, or regulatory compliance.
  3. Evaluate the root causes of non-conformities to determine underlying issues contributing to the identified problems.
  4. Develop CAPA plans to
address identified non-conformities and prevent recurrence of similar issues in the future.
  • Assign responsibility for implementing CAPA actions to relevant personnel and establish timelines for completion.
  • Implement CAPA actions according to the defined plan, ensuring that they are effective in addressing root causes and preventing recurrence of non-conformities.
  • Monitor the implementation of CAPA actions and verify their effectiveness through follow-up activities, such as re-audits, inspections, or performance evaluations.
  • Document all CAPA activities, including the rationale for CAPA actions, responsible personnel, completion dates, and verification outcomes.
  • Review and evaluate the effectiveness of CAPA actions periodically to identify any new non-conformities or opportunities for improvement.
  • Communicate CAPA outcomes and lessons learned to relevant stakeholders, including study personnel, management, sponsors, and regulatory authorities.
  • Abbreviations

    • SOP – Standard Operating Procedure
    • BA – Bioavailability
    • BE – Bioequivalence
    • QA – Quality Assurance
    • CAPA – Corrective and Preventative Actions

    Documents

    • CAPA Request Form
    • CAPA Plan
    • CAPA Implementation Records
    • CAPA Verification Reports

    Reference

    International Council for Harmonisation (ICH) Q9 Quality Risk Management guidelines and relevant regulatory guidelines for implementing CAPA in the pharmaceutical industry.

    SOP Version

    Version 1.0

    See also  SOP for Cross-validation of Bioanalytical Methods
    Bioequivalence Bioavailability Study Tags:AUC (area under the curve), BE assessment, Bioavailability study, Bioequivalence study, clinical trials, Cmax (maximum concentration), Comparative pharmacokinetics, Drug absorption, Drug absorption rate, Drug bioanalysis, Drug development, Drug dissolution, Drug formulation, Drug metabolism, In vitro bioequivalence, In vivo bioavailability, Pharmacokinetic parameters, Pharmacokinetics, SOP for Bioavailability study, SOP for Bioequivalence study, Therapeutic equivalence, Tmax (time to maximum concentration)

    Post navigation

    Previous Post: SOP for Responding to Audit Findings
    Next Post: SOP for Handling Study Dropouts

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version